drugset / Trial / NCT00295750
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The study was a three-arm, active-control, multi-centre, parallel group study.
Timeline
- Start
- 2006-02
- Primary completion
- 2007-10
- Completion
- 2007-10
Publications
- Results Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531-8. doi: 10.1111/j.1464-410X.2008.08183.x.
- Zengerling F, Jakob JJ, Schmidt S, Meerpohl JJ, Blumle A, Schmucker C, Mayer B, Kunath F. Degarelix for treating advanced hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD012548. doi: 10.1002/14651858.CD012548.pub2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 80 mg | Subcutaneous |
| Subject | Degarelix | Other / unclassified | 160 mg | Subcutaneous |
| Comparator | Leuprolide | Other / unclassified | 7.5 mg | Intramuscular |